睿知中国医院研究地图
候选清单

上海复旦大学

复旦大学附属华山医院

Huashan Hospital

在本站收录的 53 种疾病中,这家医院列在其中 26 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

复旦大学附属华山医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma12 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma62 篇牵头论文牵头 1 项开放试验
  3. 胃癌Stomach cancer22 篇牵头论文牵头 6 项开放试验
  4. 脊索瘤Chordoma4 篇牵头论文
  5. 骨肉瘤Osteosarcoma2 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  8. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  9. 多发性骨髓瘤Multiple myeloma5 篇牵头论文
  10. 血友病 AHaemophilia A1 篇牵头论文
  11. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder23 篇牵头论文牵头 1 项开放试验
  12. IgG4相关性疾病IgG4-related disease0 篇牵头论文
  13. 重症肌无力Myasthenia gravis31 篇牵头论文牵头 4 项开放试验
  14. 烟雾病Moyamoya disease17 篇牵头论文
  15. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
  16. 特发性肺纤维化Idiopathic pulmonary fibrosis7 篇牵头论文
  17. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis10 篇牵头论文
  18. 脊髓性肌萎缩症Spinal muscular atrophy11 篇牵头论文
  19. 庞贝病Pompe disease1 篇牵头论文
  20. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  21. 白塞病Behçet disease1 篇牵头论文
  22. IgA 肾病IgA nephropathy6 篇牵头论文
  23. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  24. 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
  25. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa2 篇牵头论文
  26. 遗传性血管性水肿Hereditary angioedema1 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、视网膜母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、法布雷病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.4%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 5520232024: 2220242025: 332025

上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因影像与人工智能免疫治疗
牵头的论文12
  1. The carcinogenesis of esophageal squamous cell cancer is positively regulated by USP13 through WISP1 deubiquitination.2025BioFactors (Oxford, England)
  2. The comprehensive oral microbiome landscape unveils its interplay with poor oral health in esophageal squamous cell carcinoma risk.2025Cell reports. Medicine免费全文
  3. Cancer-associated fibroblasts promote growth and dissemination of esophageal squamous cell carcinoma cells by secreting WNT family member 5A.2025Molecular and cellular biochemistry
  4. Metabolism score and machine learning models for the prediction of esophageal squamous cell carcinoma progression.2024Cancer science免费全文
  5. Rad51 and Systemic Inflammatory Indicators as Novel Prognostic Markers in Esophageal Squamous Cell Carcinoma.2024Technology in cancer research & treatment免费全文
  6. Reconstruction using the colon or jejunum in patients with synchronous advanced esophageal and gastric cancers: a retrospective study from a single institutional database.2023BMC surgery免费全文
  7. Dasabuvir suppresses esophageal squamous cell carcinoma growth in vitro and in vivo through targeting ROCK1.2023Cell death & disease免费全文
  8. Single-cell sequencing of multi-region resolves geospatial architecture and therapeutic target of endothelial cells in esophageal squamous cell carcinoma.2023Clinical and translational medicine免费全文
  9. Grading criteria for venous invasion in thoracic esophageal squamous cell carcinoma.2023Journal of cardiothoracic surgery免费全文
  10. ESRRG-PKM2 axis reprograms metabolism to suppress esophageal squamous carcinoma progression and enhance anti-PD-1 therapy efficacy.2023Journal of translational medicine免费全文
  11. The prognostic value of separate lymphatic invasion and vascular invasion in oesophageal squamous cell carcinoma: a meta-analysis and systematic review.2022BMC cancer免费全文
  12. Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.2022Neoplasma
PubMed 以外找到的论文(未计入)9
  1. 148P Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial2024Immuno-Oncology Technology论文
  2. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  3. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  4. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  5. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  6. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  7. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  8. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  9. Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.2022Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 62 篇,占 0.4%。

牵头论文
62
2021–2025 年
牵头试验
8
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 171720222023: 8820232024: 161620242025: 12122025

上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
    分期
    不分期
    开始
    2025-12
    登记号
    NCT07268131

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属华山医院上海

  2. 正在招募
    Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
    分期
    II期
    开始
    2025-11
    登记号
    NCT07331883

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院;另有 2 家列出的医院为研究中心上海、长春

  3. 正在招募
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    分期
    未注明
    开始
    2022-09
    登记号
    NCT06822413

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 3 家列出的医院为研究中心上海、南昌、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科影像/核医学科消化/肝病科
牵头的论文62
  1. A Predictive Model Study on Differentiating Intrahepatic Cholangiocarcinoma From Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound, Shear Wave Elastography, and Clinical Feature-Based Nomogram.2026Journal of clinical ultrasound : JCU
  2. Activatable Sulfur Dioxide Nanosonosensitizer Enables Precisely Controllable Sono-Gaseous Checkpoint Trimodal Therapy for Orthotopic Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients.2025Antiviral research
  4. Nanomedicine-unlocked radiofrequency dynamic therapy dampens incomplete radiofrequency ablation-arised immunosuppression to suppress cancer relapse.2025Biomaterials
  5. Comparison of 11C-Acetate and 18F-FDG PET/CT for Immune Infiltration and Prognosis in Hepatocellular Carcinoma.2025Cancer science免费全文
  6. Population stratification using MASLD polygenic risk score improves severe liver disease prediction by clinical fibrosis scores.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. Prognostic and diagnostic value of [18F]FDG, 11C-acetate, and [68Ga]Ga-FAPI-04 PET/CT for hepatocellular carcinoma.2025European radiology
  8. A novel nomogram to predict the recurrence of hepatocellular carcinoma after liver transplantation using extended selection criteria.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  9. Adjuvant lenvatinib in combination with transarterial chemoembolization for hepatocellular carcinoma patients with high risk of postoperative recurrence: A multicenter prospective cohort study.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  10. Integrated Genetic Information of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Traits Improves Hepatocellular Carcinoma Risk Stratification and Screening.2025JCO precision oncology
  11. HBV sequence integrated to enhancer acting as oncogenic driver epigenetically promotes hepatocellular carcinoma development.2025Journal of experimental & clinical cancer research : CR免费全文
  12. Cholesterol suppresses AMFR-mediated PDL1 ubiquitination and degradation in HCC.2025Molecular and cellular biochemistry免费全文
  13. Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma.2025Signal transduction and targeted therapy免费全文
  14. The Absence of Intra-Tumoral Tertiary Lymphoid Structures is Associated with a Worse Prognosis and mTOR Signaling Activation in Hepatocellular Carcinoma with Liver Transplantation: A Multicenter Retrospective Study.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  15. Deciphering the role of KLRB1: a novel prognostic indicator in hepatocellular carcinoma.2024BMC gastroenterology免费全文
  16. Cross-institutional evaluation of deep learning and radiomics models in predicting microvascular invasion in hepatocellular carcinoma: validity, robustness, and ultrasound modality efficacy comparison.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  17. Acetyl-CoA metabolic accumulation promotes hepatocellular carcinoma metastasis via enhancing CXCL1-dependent infiltration of tumor-associated neutrophils.2024Cancer letters
  18. Circular RNA circESYT2 serves as a microRNA-665 sponge to promote the progression of hepatocellular carcinoma through ENO2.2024Cancer science免费全文
  19. ASB3 promotes hepatocellular carcinoma progression by mediating DR5 ubiquitination in TRAIL resistance.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  20. Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma.2024Journal for immunotherapy of cancer免费全文
  21. Integration of single-cell and spatial transcriptome sequencing identifies CDKN2A as a senescent biomarker in endothelial cells implicating hepatocellular carcinoma malignancy.2024Journal of cancer research and clinical oncology免费全文
  22. Immune- and metabolism-related gene signature analysis uncovers the prognostic and immune microenvironments of hepatocellular carcinoma.2024Journal of cancer research and clinical oncology免费全文
  23. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.2024Journal of hematology & oncology免费全文
  24. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.2024Journal of medicinal chemistry
  25. Preoperative Ultrasound Radomics to Predict Posthepatectomy Liver Failure in Patients With Hepatocellular Carcinoma.2024Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  26. Stomatin-like protein 2 promotes cell proliferation and survival under 5-Fluorouracil stress in hepatocellular carcinoma.2024Molecular biology reports
  27. Automatic segmentation of hepatocellular carcinoma on dynamic contrast-enhanced MRI based on deep learning.2024Physics in medicine and biology
  28. Nuclear translocation of metabolic enzyme PKM2 participates in high glucose-promoted HCC metastasis by strengthening immunosuppressive environment.2024Redox biology免费全文
  29. Nomogram based on liver stiffness and spleen area with ultrasound for posthepatectomy liver failure: A multicenter study.2024World journal of gastroenterology免费全文
  30. Spleen to non-cancerous liver volume ratio predicts liver cirrhosis in hepatocellular carcinoma patients.2023Abdominal radiology (New York)RCT
  31. SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway.2023Acta biochimica et biophysica Sinica免费全文
  32. Fusing Positive and Negative CT Contrast Nanoagent for the Sensitive Detection of Hepatoma.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  33. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.2023European journal of internal medicine
  34. The m6A-related gene signature stratifies poor prognosis patients and characterizes immunosuppressive microenvironment in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  35. The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  36. An Angiogenic Gene Signature for Prediction of the Prognosis and Therapeutic Responses of Hepatocellular Carcinoma.2023International journal of molecular sciences免费全文
  37. CircularRNA Hsa_circ_0093335 promotes hepatocellular carcinoma progression via sponging miR-338-5p.2023Journal of cellular and molecular medicine免费全文
  38. Alcohol consumption and hepatocellular carcinoma: novel insights from a prospective cohort study and nonlinear Mendelian randomization analysis.2022BMC medicine免费全文
  39. Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.2022Cancer research免费全文
  40. 27-Hydroxycholesterol promotes metastasis by SULT2A1-dependent alteration in hepatocellular carcinoma.2022Cancer science免费全文
  41. Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma.2022Cell reports
  42. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma.2022Cellular & molecular immunology免费全文
  43. LncRNA GASAL1 promotes hepatocellular carcinoma progression by up-regulating USP10-stabilized PCNA.2022Experimental cell research
  44. Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma.2022Frontiers of medicine
  45. Significance of Identifying Key Genes Involved in HBV-Related Hepatocellular Carcinoma for Primary Care Surveillance of Patients with Cirrhosis.2022Genes免费全文
  46. Immunotherapy for hepatobiliary malignancies: Progress and prospective.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  47. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  48. Biomarkers for response to immunotherapy in hepatobiliary malignancies.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  49. Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.2022Journal of hepatology
  50. Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study.2022Journal of medical virology免费全文
  51. RNF4 silencing induces cell growth arrest and DNA damage by promoting nuclear targeting of p62 in hepatocellular carcinoma.2022Oncogene
  52. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.2022PeerJ免费全文
  53. Predictive Value of Platelet-Related Measures in Patients with Hepatocellular Carcinoma.2022Technology in cancer research & treatment免费全文
  54. Radiomics for the detection of microvascular invasion in hepatocellular carcinoma.2022World journal of gastroenterology免费全文
  55. Integrated bioinformatics analysis revealed the regulation of angiogenesis by tumor cells in hepatocellular carcinoma.2021Bioscience reports免费全文
  56. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.2021Cancer investigation
  57. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.2021Hepatology (Baltimore, Md.)
  58. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma.2021International journal of cancer
  59. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.2021Journal of hematology & oncology免费全文
  60. Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1): A Novel Predictor for Recurrence of Hepatocellular Carcinoma After Curative Resection.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  61. GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages.2021Signal transduction and targeted therapy免费全文
  62. Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.2021Signal transduction and targeted therapy免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular Carcinoma状态不明NCT06148155牵头方不分期2023-06 启动
  2. Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma状态不明NCT05105815牵头方早期I期2021-12 启动
  3. The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection状态不明NCT03253250牵头方IV期2017-09 启动
  4. TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria正在招募NCT07268131牵头方(推断)不分期2025-12 启动
  5. PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC状态不明NCT04974281牵头方(推断)早期I期2021-01 启动
  6. Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma状态不明NCT03838796牵头方(推断)不分期2019-01 启动
  7. Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma已终止NCT02748304牵头方(推断)不分期2016-04 启动
  8. Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma状态不明NCT02526043牵头方(推断)不分期2015-08 启动
  9. Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)正在招募NCT07331883研究中心II期2025-11 启动
  10. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis正在招募NCT06822413研究中心2022-09 启动
  11. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)已完成NCT04740307研究中心II期2021-03 启动
  12. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.2%。

牵头论文
22
2021–2025 年
牵头试验
9
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 5520222023: 5520232024: 4420242025: 442025

上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
    分期
    早期I期
    开始
    2026-06
    登记号
    NCT07707531

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属华山医院上海

  2. 正在招募
    A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
    分期
    不分期
    开始
    2024-01
    登记号
    NCT06300879

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属华山医院上海

  3. 正在招募
    Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
    分期
    不分期
    开始
    2024-12
    登记号
    NCT06679244

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:复旦大学附属华山医院;另有 2 家列出的医院为研究中心上海

  4. 正在招募
    Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
    分期
    II期
    开始
    2023-10
    登记号
    NCT06054906

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属华山医院上海

  5. 即将招募
    Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer
    分期
    II期
    开始
    2025-05
    登记号
    NCT06759233

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:复旦大学附属华山医院上海

  6. 即将招募
    A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer
    分期
    II期
    开始
    2025-05
    登记号
    NCT06957977

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属华山医院上海

  7. 正在招募
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    分期
    未注明
    开始
    2022-09
    登记号
    NCT06822413

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 3 家列出的医院为研究中心上海、南昌、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术腹膜转移与晚期营养与康复
论文中的科室普外/肝胆胰外科消化/肝病科病理/检验科肿瘤内科
牵头的论文22
  1. Neuroactive ligand-receptor interaction in gastric cancer: a comprehensive spatial single-cell analysis.2026Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  2. Application of Hao's Esophagogastrostomy by Fissure Technique (HEFT) in proximal gastrectomy: protocol for a prospective, multicentre, randomised controlled study.2025BMJ open免费全文
  3. Spatiotemporal Correlation Analysis for the Incidence of Esophageal and Gastric Cancer From 2010 to 2019: Ecological Study.2025JMIR cancer免费全文
  4. Shortcoming of ypStage staging system: Lack of differentiation for preoperative treatment.2025PloS one免费全文
  5. A novel anti-reflux esophagogastric anastomosis in totally laparoscopic proximal gastrectomy: Hao's esophagogastrostomy by fissure technique (HEFT).2025World journal of surgical oncology免费全文
  6. Circular RNA hsa_circ_0004650 Enhances 5-Fluorouracil Resistance in Gastric Cancer via Sponging miR-145-5p.2024Anticancer research
  7. Elucidating epigenetic landscape of gastric premalignant lesions through genome-wide mapping of 5-hydroxymethylcytosines: A 12-year median follow-up study.2024Clinical and translational medicine免费全文
  8. The safety and feasibility assessment of overlap esophagojejunostomy with self-pulling and latter transection technique in totally laparoscopic total gastrectomy.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  9. New purse-string suture clamp and multi-functional seal cap: a simple intracorporeal circular-stapled oesophagojejunostomy after laparoscopic total gastrectomy.2024Langenbeck's archives of surgery
  10. Reconstruction using the colon or jejunum in patients with synchronous advanced esophageal and gastric cancers: a retrospective study from a single institutional database.2023BMC surgery免费全文
  11. Identification of three lncRNA-related prognostic signatures in gastric cancer by integrated multi-omics analysis.2023Epigenomics
  12. The global, regional, and national burden of stomach cancer among adolescents and young adults in 204 countries and territories, 1990-2019: A population-based study.2023Frontiers in public health免费全文
  13. Systematic single-cell dissecting reveals heterogeneous oncofetal reprogramming in the tumor microenvironment of gastric cancer.2023Human cell
  14. Screening and Bioinformatics Analyses of Key miRNAs Associated with Toll-like Receptor Activation in Gastric Cancer Cells.2023Medicina (Kaunas, Lithuania)免费全文
  15. Exosome-mediated transfer of circ_0063526 enhances cisplatin resistance in gastric cancer cells via regulating miR-449a/SHMT2 axis.2022Anti-cancer drugs
  16. Effect of different oesophagojejunostomy methods on the quality of life of gastric cancer patients after totally laparoscopic total gastrectomy with self-pulling and latter transected technique: study protocol for a randomised trial.2022BMJ open免费全文
  17. Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study.2022European journal of nuclear medicine and molecular imaging
  18. Bracket-like suture method: a novel, circular marked, simplest sided purse-string suture technique for intracorporeal circular-stapled oesophagojejunostomy during laparoscopic total gastrectomy.2022Langenbeck's archives of surgery
  19. The regulation of hsacirc_004413 promotes proliferation and drug resistance of gastric cancer cells by acting as a competing endogenous RNA for miR-145-5p.2022PeerJ免费全文
  20. LINC00511 promotes gastric cancer progression by regulating SOX4 and epigenetically repressing PTEN to activate PI3K/AKT pathway.2021Journal of cellular and molecular medicine免费全文
  21. Handover method: Simple, classic and harmonized intracorporeal closure of stapled duodenal stump during laparoscopic gastrectomy.2021Journal of surgical oncology
  22. The safety and feasibility of intra-corporeal gastroduodenostomy using a self-pulling and latter transected method (Delta SPLT) in totally laparoscopic distal gastrectomy.2021Journal of surgical oncology
中文论文(未计入)2
  1. [A novel exploration of circular-stapled esophagojejunostomy in totally laparoscopic total gastrectomy: purse-string suture device with multi-functional seal cap].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Laparoscopic circular stapled gastrointestinal anastomosis using novel device of sealed cap access after total laparoscopic gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer正在招募NCT07707531牵头方早期I期2026-06 启动
  2. Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study正在招募NCT06679244牵头方不分期2024-12 启动
  3. A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique正在招募NCT06300879牵头方不分期2024-01 启动
  4. Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer正在招募NCT06054906牵头方II期2023-10 启动
  5. Metronomic Chemotherapy in Advanced Gastric Cancer状态不明NCT02855788牵头方II期2015-05 启动
  6. Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer即将招募NCT06759233牵头方(推断)II期2025-05 启动
  7. A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer即将招募NCT06957977牵头方(推断)II期2025-05 启动
  8. Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer状态不明NCT06203613牵头方(推断)不分期2023-12 启动
  9. The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites状态不明NCT02779608牵头方(推断)II期2017-01 启动
  10. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis正在招募NCT06822413研究中心2022-09 启动
  11. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 3.8%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 2220232024: 1120242025: 002025

上海有 15 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.09%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. The influence of marital status on the survival of patients with operable gastrointestinal stromal tumor: A SEER-based study.2019The International journal of health planning and management

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

上海有 34 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 15 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study.2020Journal of orthopaedic surgery and research

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.3%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 2220242025: 002025

上海有 16 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层肾脏与骨骼并发症
论文中的科室神经外科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

上海有 9 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 23 篇,占 4.7%。

牵头论文
23
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 7720222023: 3320232024: 2220242025: 882025

上海有 4 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    HANDLE-a Real World Study on Satralizumab in NMOSD
    分期
    未注明
    开始
    2025-03
    登记号
    NCT06829524

    年龄 12 岁 至 未注明(登记的条件)

    牵头:复旦大学附属华山医院上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断生物制剂预防复发
论文中的科室神经内科病理/检验科影像/核医学科
牵头的论文23
  1. Concomitant Sjögren's disease in patients with NMOSD: impacts on neurologic disease severity and recurrence.2025Arthritis research & therapy免费全文
  2. Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab.2025Autoimmunity reviews
  3. Outcomes and predictors of relapse and severe pneumonia in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder receiving inebilizumab: a prospective cohort study.2025Frontiers in immunology免费全文
  4. Dysregulated Tfh/B cells and their interactions in neuromyelitis optica spectrum disorder.2025Frontiers in immunology免费全文
  5. Eculizumab for the acute attack of neuromyelitis optica spectrum disorder.2025Frontiers in immunology免费全文
  6. Comparison of the clinical and laboratory characteristics of neuromyelitis optica spectrum disorder with or without cerebrospinal fluid oligoclonal bands: a cohort with 36-month follow-up.2025Frontiers in immunology免费全文
  7. Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis optica spectrum disorder.2025Journal of neurology
  8. KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort.2025Journal of neurology, neurosurgery, and psychiatry
  9. First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders.2024CNS neuroscience & therapeutics免费全文
  10. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.2024European radiology
  11. Causal associations between prodromal infection and neuromyelitis optica spectrum disorder: A Mendelian randomization study.2023European journal of neurology
  12. Clinical feature and disease outcome in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder: a Chinese study.2023Journal of neurology, neurosurgery, and psychiatry
  13. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.2023Neurology(R) neuroimmunology & neuroinflammation免费全文
  14. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.2022European journal of neurology
  15. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.2022European journal of neurology
  16. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.2022Frontiers in immunology免费全文
  17. Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.2022JAMA network open免费全文
  18. The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China.2022Multiple sclerosis and related disorders
  19. Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus.2022Multiple sclerosis and related disorders
  20. Efficacy and safety of rehabilitation exercise in neuromyelitis optica spectrum disorder during the acute phase: A prospective cohort study.2022Multiple sclerosis and related disorders
  21. Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients.2021European journal of neurology
  22. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.2021Frontiers in immunology免费全文
  23. Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder.2021Multiple sclerosis and related disorders
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. HANDLE-a Real World Study on Satralizumab in NMOSD正在招募NCT06829524牵头方2025-03 启动
  2. BLAZE-Limiting Approach in NMOSD已完成NCT06888622牵头方2023-10 启动
  3. An Open Label Study of the Effects of SHR1459 in NMOSDs Patients已完成NCT04670770研究中心II期2021-01 启动
  4. A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders已完成NCT04146285研究中心I期2020-09 启动
PubMed 以外找到的论文(未计入)5
  1. B-103 KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort2025Clinical Chemistry会议摘要
  2. Satralizumab Treatment in Chinese Patients with AQP4-ab-positive Neuromyelitis Optica Specturm Disorder: A Prospective Study (P9-1.015)2025Neurology论文
  3. The effect of health-related hardiness education in patients with neuromyelitis optica spectrum disorders2023Research Square预印本
  4. Neuromyelitis optica spectrum disorders and pregnancy2022DOAJ (DOAJ: Directory of Open Access Journals)论文
  5. Is low threshold of B cells an obligatory monitoring indicator of repeated RTX infusion in the treatment of Neuromyelitis Optica spectrum disorder? – A report of two cases2021Neuroimmunology Reports论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年没有牵头IgG4相关性疾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 4 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 31 篇,占 6.2%。

牵头论文
31
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 8820222023: 3320232024: 5520242025: 992025

上海有 7 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
    分期
    未注明
    开始
    2024-02
    登记号
    NCT04535843

    年龄 0 岁 至 90 岁(登记的条件)

    牵头:复旦大学附属华山医院;另有 1 家列出的医院为研究中心上海

  2. 正在招募
    Myasthenia Gravis Registry in China
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06241521

    年龄未注明(登记的条件)

    牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙

  3. 正在招募
    Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
    分期
    未注明
    开始
    2023-08
    登记号
    NCT07146425

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属华山医院上海

  4. 即将招募
    An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
    分期
    I期
    开始
    2025-02
    登记号
    NCT06759948

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属华山医院上海

  5. 正在招募
    A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
    分期
    II期
    开始
    2026-08
    登记号
    NCT07622342

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、长沙

  6. 正在招募
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    分期
    I期
    开始
    2025-09
    登记号
    NCT07215650

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、天津、太原、广州、成都、贵阳、郑州、长春

  7. 正在招募
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06447597

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、长春、长沙

  8. 正在招募
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    分期
    III期
    开始
    2024-06
    登记号
    NCT06463587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、广州、成都、武汉、沈阳、石家庄、蚌埠、遵义、郑州、长春、长沙

  9. 正在招募
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    分期
    II期
    开始
    2022-07
    登记号
    NCT05067348

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心上海、北京、天津、成都、西安、长沙

  10. 正在招募
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    分期
    III期
    开始
    2021-07
    登记号
    NCT04951622

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙

  11. 即将招募
    An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
    分期
    I期
    开始
    2026-09
    登记号
    NCT07818291

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断生物制剂与补体抑制剂危象与重症监护
论文中的科室神经内科
牵头的论文31
  1. In-Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis.2026Annals of clinical and translational neurology免费全文
  2. Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis.2026Clinical immunology (Orlando, Fla.)
  3. Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab.2025Autoimmunity reviews
  4. Association of blocking acetylcholine receptor antibodies with clinical subtypes and disease severity in myasthenia gravis.2025Clinica chimica acta; international journal of clinical chemistry
  5. Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study.2025Clinical immunology (Orlando, Fla.)
  6. Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.2025Frontiers in immunology免费全文
  7. Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis.2025Frontiers in immunology免费全文
  8. Distal muscle weakness as the main onset symptom in thymoma-associated myasthenia gravis: a case report and literature review.2025Frontiers in immunology免费全文
  9. Clinical outcome and peripheral CD4+ T profile in impending myasthenic crisis: A prospective cohort study.2025Journal of neuroimmunology
  10. Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series.2025Journal of neuroimmunology
  11. The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.2025Neurocritical care
  12. Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China.2024Annals of clinical and translational neurology免费全文
  13. A predictive nomogram for short-term outcomes of myasthenia gravis patients treated with low-dose rituximab.2024CNS neuroscience & therapeutics免费全文
  14. Clinical outcome and peripheral immune profile of myasthenic crisis with omicron infections: A prospective cohort study.2024Clinical immunology (Orlando, Fla.)
  15. Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series.2024Frontiers in immunology免费全文
  16. Nomogram for predicting pregnancy-related relapse of myasthenia gravis.2024Orphanet journal of rare diseases免费全文
  17. Autoantibody levels as biomarkers of disease activity in the management of myasthenia gravis.2023European journal of neurology
  18. Peripheral immune landscape for hypercytokinemia in myasthenic crisis utilizing single-cell transcriptomics.2023Journal of translational medicine免费全文
  19. Myasthenic crisis in thymoma-associated myasthenia gravis: a multicenter retrospective cohort study.2023Neuromuscular disorders : NMD
  20. Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis.2022BMC immunology免费全文
  21. Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: A prospective cohort study.2022Clinical immunology (Orlando, Fla.)
  22. Pneumonia in myasthenia gravis: Microbial etiology and clinical management.2022Frontiers in cellular and infection microbiology免费全文
  23. Herpesvirus entry mediator on T cells as a protective factor for myasthenia gravis: A Mendelian randomization study.2022Frontiers in immunology免费全文
  24. A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation.2022Frontiers in immunology免费全文
  25. Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets.2022Journal of neuroimmunology
  26. Pneumonia and systemic inflammatory response syndrome as predictors for difficult-/prolonged-weaning after invasive ventilation in myasthenic crisis: A retrospective analysis of a Chinese cohort.2022Neuromuscular disorders : NMD
  27. Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis.2022Orphanet journal of rare diseases免费全文
  28. In-depth peripheral CD4+ T profile correlates with myasthenic crisis.2021Annals of clinical and translational neurology免费全文
  29. The role of innate immunity in myasthenia gravis.2021Autoimmunity reviews
  30. Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis.2021Journal of translational medicine免费全文
  31. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.2021Muscle & nerve
它在 ClinicalTrials.gov 上的全部试验(任何状态)24
  1. Myasthenia Gravis Registry in China正在招募NCT06241521牵头方2024-02 启动
  2. Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China正在招募NCT04535843牵头方2024-02 启动
  3. Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis正在招募NCT07146425牵头方2023-08 启动
  4. Study of Myasthenic Crisis in China状态不明NCT04837625牵头方2020-10 启动
  5. Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study已完成NCT04431895牵头方早期I期2020-06 启动
  6. An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis即将招募NCT06759948牵头方(推断)I期2025-02 启动
  7. An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis即将招募NCT07818291研究中心I期2026-09 启动
  8. A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis正在招募NCT07622342研究中心II期2026-08 启动
  9. Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)正在招募NCT07215650研究中心I期2025-09 启动
  10. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.正在招募NCT06447597研究中心II/III期2024-07 启动
  11. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)正在招募NCT06463587研究中心III期2024-06 启动
  12. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis正在招募NCT05067348研究中心II期2022-07 启动
  13. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis正在招募NCT04951622研究中心III期2021-07 启动
  14. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)进行中,不再招募NCT06456580研究中心III期2024-07 启动
  15. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis进行中,不再招募NCT06298552研究中心III期2024-04 启动
  16. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis进行中,不再招募NCT06558279研究中心III期2024-09 启动
  17. Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis状态不明NCT05716035研究中心II/III期2023-04 启动
  18. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动
  19. Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis已完成NCT05332210研究中心III期2022-06 启动
  20. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis已终止NCT04963270研究中心III期2021-10 启动
  21. Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients已完成NCT05039190研究中心III期2021-09 启动
  22. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis进行中,不再招募NCT05070858研究中心III期2021-12 启动
  23. A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients已完成NCT04346888研究中心II期2020-07 启动
  24. A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis已完成NCT04302103研究中心II期2020-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 17 篇,占 4.8%。

牵头论文
17
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 4420222023: 4420232024: 1120242025: 442025

上海有 4 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07894107

    年龄 12 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州

  2. 正在招募
    Registry of Multicenter Brain-Heart Comorbidity in China
    分期
    未注明
    开始
    2012-01
    登记号
    NCT05961748

    年龄 18 岁 至 未注明(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 4 家列出的医院为研究中心上海、北京、哈尔滨、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与脑血流血管重建手术中风与出血
论文中的科室神经外科
牵头的论文17
  1. Non-Invasive Diagnosis of Moyamoya Disease Using Serum Metabolic Fingerprints and Machine Learning.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Inhalational versus intravenous anesthetic for cerebrovascular accident outcomes after surgical revascularization for adult moyamoya disease.2025BMC anesthesiology免费全文
  3. The cerebellar glucose metabolism in moyamoya vasculopathy and its correlation with neurocognitive performance after cerebral revascularization surgery: a [18F]FDG PET study.2025European journal of nuclear medicine and molecular imaging免费全文
  4. In-depth cerebrovascular lipidomics profiling for discovering novel biomarkers and mechanisms in moyamoya and intracranial atherosclerotic disease.2025International journal of surgery (London, England)免费全文
  5. Individualised evaluation based on pathophysiology for moyamoya vasculopathy: application in surgical revascularisation.2024Stroke and vascular neurology免费全文
  6. How I do it: direct pressure measurement in moyamoya bypass.2023Acta neurochirurgica
  7. Brain perfusion, cognition, and plasma Alzheimer's biomarkers in moyamoya disease.2023Alzheimer's & dementia : the journal of the Alzheimer's Association
  8. 18F-FDG PET and a classifier algorithm reveal a characteristic glucose metabolic pattern in adult patients with moyamoya disease and vascular cognitive impairment.2023Brain imaging and behavior
  9. Learning spatiotemporal features of DSA using 3D CNN and BiConvGRU for ischemic moyamoya disease detection.2023The International journal of neuroscience
  10. How I do it: superficial temporal artery to middle cerebral artery bypass for moyamoya disease.2022Acta neurochirurgica
  11. A Review of Artificial Intelligence in Cerebrovascular Disease Imaging: Applications and Challenges.2022Current neuropharmacology免费全文
  12. Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.2022Current neuropharmacology免费全文
  13. Application of intraoperative electrocorticography in bypass surgery for adult moyamoya disease: a preliminary study.2022Frontiers in bioscience (Landmark edition)
  14. The First 24 h Hemodynamic Management in NICU after Revascularization Surgery in Moyamoya Disease.2021Behavioural neurology免费全文
  15. Introduction. Translational research advances in the evaluation and management of moyamoya disease.2021Neurosurgical focus
  16. Faded Critical Dynamics in Adult Moyamoya Disease Revealed by EEG and fMRI.2021Oxidative medicine and cellular longevity免费全文
  17. Preliminary Study on the Application of Ultrahigh Field Magnetic Resonance in Moyamoya Disease.2021Oxidative medicine and cellular longevity免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Neurocognitive and Radiological Assessments in Adult Moyamoya Undergoing Surgery状态不明NCT02305407牵头方不分期2016-03 启动
  2. The Adult Hemorrhagic Moyamoya Surgery Study状态不明NCT02319980牵头方III期2015-05 启动
  3. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome正在招募NCT07894107研究中心2026-08 启动
  4. Registry of Multicenter Brain-Heart Comorbidity in China正在招募NCT05961748研究中心2012-01 启动
PubMed 以外找到的论文(未计入)12
  1. Dual-Branch X-CLIP with Feature Purification for Multi-Section DSA Imaging-Based Cerebrovascular Disease Classification2025International Conference on Advanced Algorithms and Neural Networks (AANN)会议论文
  2. Perioperative management for patients with moyamoya disease: complications’ definition, technical advances, and outcomes2025Research Square预印本
  3. 3D DSA-Guided Keyhole STA-MCA Bypass in Moyamoya Vasculopathy2024Springer eBooks书籍章节
  4. Intraoperative contrast-enhanced ultrasound evaluates the hemodynamic change of cerebral revascularization in adult moyamoya disease: Preliminary results2023WFUMB Ultrasound Open论文
  5. The Role of Flow-Augmentation Bypass in Moyamoya Disease and Hemodynamic Ischemic Stroke2023Brain and Spine论文
  6. Analysis of middle cerebral artery blood flow in moyamoya disease and comparison of orthodromic and antidromic bypass2022DOAJ (DOAJ: Directory of Open Access Journals)论文
  7. Identification of Vascular Cognitive Impairment in Adult Moyamoya Disease via Integrated Graph Convolutional Network2022Lecture notes in computer science会议论文
  8. Computational Fluid Dynamics Study of Cerebral Revascularization for Moyamoya Disease2021Springer eBooks书籍章节
  9. Functional Magnetic Resonance Imaging Study of Cerebral Revascularization in Moyamoya Disease2021Springer eBooks书籍章节
  10. Long-Term Outcome in China2021Springer eBooks书籍章节
  11. Superficial Temporal Artery-Middle Cerebral Artery Bypass2021Springer eBooks书籍章节
  12. Superficial Temporal Artery-Middle Cerebral Artery Bypass Combined with Encephalo-Duro-Myo-Synangiosis in Treating Moyamoya Disease2021Springer eBooks书籍章节

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

上海有 9 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.7%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 3320232024: 1120242025: 112025

上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文7
  1. Iron dysregulation and ferroptosis are associated with pulmonary fibrosis: Insight from idiopathic pulmonary fibrosis, systemic sclerosis, and COVID-19 patients.2025Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
  2. Icariside II modulates pulmonary fibrosis via PI3K/Akt/β-catenin pathway inhibition of M2 macrophage program.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  3. Pulmonary fibrosis model of mice induced by different administration methods of bleomycin.2023BMC pulmonary medicine
  4. Network pharmacology and experiments in vivo and in vitro reveal that the Jia-Wei-Bu-Shen-Yi-Qi formula (JWBSYQF) and its active ingredient baicalein ameliorate BLM-induced lung fibrosis in mice via PI3K/Akt signaling pathway.2023Journal of ethnopharmacology
  5. Adipose-derived mesenchymal stem cell therapy for reverse bleomycin-induced experimental pulmonary fibrosis.2023Scientific reports
  6. Exploring the comorbidity mechanisms between asthma and idiopathic pulmonary fibrosis and the pharmacological mechanisms of Bu-Shen-Yi-Qi decoction therapy via network pharmacology.2022BMC complementary medicine and therapies
  7. Endocannabinoid signalling/cannabinoid receptor 2 is involved in icariin-mediated protective effects against bleomycin-induced pulmonary fibrosis.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
早期论文(2016–2020 年)1
  1. Clinical Association of Chemokine (C-X-C motif) Ligand 1 (CXCL1) with Interstitial Pneumonia with Autoimmune Features (IPAF).2016Scientific reports

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 10 篇,占 1.3%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 4420232024: 1120242025: 222025

上海有 17 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Research on Wireless Brain Implant System for General Control of External Devices
    分期
    不分期
    开始
    2025-03
    登记号
    NCT06829212

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科影像/核医学科
牵头的论文10
  1. Prognostic Value of Cerebrospinal Fluid and Serum Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Correlation Study.2025Brain and behavior
  2. Integrated profiling of iPSC-derived motor neurons carrying C9orf72, FUS, TARDBP, or SOD1 mutations.2025Stem cell reports
  3. Inflammation and Brain Structure in Alzheimer's Disease and Other Neurodegenerative Disorders: a Mendelian Randomization Study.2024Molecular neurobiology
  4. Brain region-specific synaptic function of FUS underlies the FTLD-linked behavioural disinhibition.2023Brain : a journal of neurology
  5. A new ERBB4 variant in amyotrophic lateral sclerosis type 19: Case report and review of the literature.2023Clinical neurology and neurosurgery
  6. Iron quantitative analysis of motor combined with bulbar region in M1 cortex may improve diagnosis performance in ALS.2023European radiology
  7. Associations of cardiovascular risk factors and lifestyle behaviors with neurodegenerative disease: a Mendelian randomization study.2023Translational psychiatry
  8. Investigating Casual Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases: A Mendelian Randomization Study.2022Journal of Alzheimer's disease : JAD
  9. The function of FUS in neurodevelopment revealed by the brain and spinal cord organoids.2022Molecular and cellular neurosciences
  10. UNC13A Gene Brings New Hope for ALS Disease-Modifying Drugs.2022Neuroscience bulletin
早期论文(2016–2020 年)10
  1. An exon 5 mutation (c.425G>C, p.Gly141Ala) in the SOD1 gene in a Chinese family associated with incomplete penetrance.2020Amyotrophic lateral sclerosis & frontotemporal degeneration
  2. Familial flail leg ALS caused by PFN1 mutation.2020Journal of neurology, neurosurgery, and psychiatry
  3. Tau Accumulation via Reduced Autophagy Mediates GGGGCC Repeat Expansion-Induced Neurodegeneration in Drosophila Model of ALS.2020Neuroscience bulletin
  4. Amyotrophic lateral sclerosis due to a SOD1 mutation and X-linked recessive bulbospinal neuronopathy in a single family.2019Acta neurologica Belgica
  5. Split-hand phenomenon quantified by the motor unit number index for distinguishing cervical spondylotic amyotrophy from amyotrophic lateral sclerosis.2019Neurophysiologie clinique = Clinical neurophysiology
  6. Radial diffusivity as an imaging biomarker for early diagnosis of non-demented amyotrophic lateral sclerosis.2018European radiology
  7. The investigation of genetic and clinical features in Chinese patients with juvenile amyotrophic lateral sclerosis.2017Clinical genetics
  8. Repetitive nerve stimulation as a diagnostic aid for distinguishing cervical spondylotic amyotrophy from amyotrophic lateral sclerosis.2017European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  9. Compound Muscle Action Potential Decrement to Repetitive Nerve Stimulation Between Hirayama Disease and Amyotrophic Lateral Sclerosis.2017Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
  10. A novel mutation of VAPB in one Chinese familial amyotrophic lateral sclerosis pedigree and its clinical characteristics.2017Journal of neurology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Research on Wireless Brain Implant System for General Control of External Devices正在招募NCT06829212研究中心不分期2025-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年中国大陆作者发表的 55 篇脊髓性肌萎缩症 PubMed 英文论文中,这家医院牵头了 11 篇,占 20.0%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 5520232024: 1120242025: 002025

上海有 6 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文11
  1. The clinical characteristics of Hirayama disease in females.2024Neurologia
  2. The role of leisure-time physical activity in maintaining cervical lordosis after anterior cervical fusion and its impact on the motor function in patients with hirayama disease: a retrospective cohort analysis.2023BMC musculoskeletal disorders
  3. Association of joint hypermobility with range of cervical motion and its impact on the motor unit loss in patients with Hirayama disease.2023Muscle & nerve
  4. Loss of cervical sagittal alignment worsens the cervical spinal lesions in patients with Hirayama disease.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  5. Changes in Self-Esteem in Patients with Hirayama Disease and its Association with Prognosis After Anterior Cervical Fusion Procedures.2023World neurosurgery
  6. Efficacy of Anterior Cervical Discectomy and Fusion for Female Patients with Hirayama Disease.2023World neurosurgery
  7. How to reconstruct the lordosis of cervical spine in patients with Hirayama disease? A finite element analysis of biomechanical changes focusing on adjacent segments after anterior cervical discectomy and fusion.2022Journal of orthopaedic surgery and research
  8. Why the patients with Hirayama disease have abnormal cervical sagittal alignment? A radiological measurement analysis of posterior cervical extensors.2022Journal of orthopaedic surgery and research
  9. Teaching NeuroImages: Hirayama Disease With Symmetric Atrophy of Bilateral Distal Upper Extremities.2021Neurology
  10. Quantitative assessment of motor impairment and surgical outcome in Hirayama disease with proximal involvement using motor unit number index.2021Neurophysiologie clinique = Clinical neurophysiology
  11. The Short-Term to Midterm Follow-Up of Patients with Hirayama Disease After Anterior Cervical Discectomy and Fusion.2021World neurosurgery
早期论文(2016–2020 年)14
  1. Establishment of a clinician-led guideline on the diagnosis and treatment of Hirayama disease using a modified Delphi technique.2020Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  2. Analysis of the Effect of Surgical Treatment for the Patients with Hirayama Disease from the Perspective of Cervical Spine Sagittal Alignment.2020World neurosurgery
  3. Snake-Eyes Appearance on MRI Occurs during the Late Stage of Hirayama Disease and Indicates Poor Prognosis.2019BioMed research international
  4. The evaluation on neural status of cervical spinal cord in normal and Hirayama disease using diffusion tensor imaging.2019European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  5. Factors Affecting the Surgical Outcomes of Hirayama Disease: A Retrospective Analysis of Preoperative Magnetic Resonance Imaging Features of the Cervical Spine.2019World neurosurgery
  6. CAN anterior cervical fusion procedures prevent the progression of the natural course of Hirayama disease? An ambispective cohort analysis.2018Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  7. Cortical Activation Changes in Hirayama Disease After Anterior Cervical Decompression and Fusion.2018World neurosurgery
  8. Dynamic Cervical Radiographs in Patients with Hirayama Disease: An Unneglectable Factor on the Choice of Surgery Options.2018World neurosurgery
  9. Changes in the soleus H-reflex test and correlations between its results and dynamic magnetic resonance imaging abnormalities in patients with Hirayama disease.2017Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  10. A double determination of central motor conduction time in the assessment of Hirayama disease.2017Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  11. Motor unit number estimation in the quantitative assessment of severity and progression of motor unit loss in Hirayama disease.2017Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  12. Compound Muscle Action Potential Decrement to Repetitive Nerve Stimulation Between Hirayama Disease and Amyotrophic Lateral Sclerosis.2017Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
  13. Risk Factors for Surgical Results of Hirayama Disease: A Retrospective Analysis of a Large Cohort.2017World neurosurgery
  14. A study of dynamic F-waves in juvenile spinal muscular atrophy of the distal upper extremity (Hirayama disease).2016Journal of the neurological sciences
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Adult Spinal Muscular Atrophy (SMA) China Registry进行中,不再招募NCT05618379研究中心2023-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

庞贝病

Pompe disease

2021–2025 年中国大陆作者发表的 30 篇庞贝病 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.3%。

牵头论文
1
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

上海有 4 家医院列在庞贝病下全国有 30 家医院列在庞贝病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文1
  1. High-risk screening for late-onset Pompe disease in China: An expanded multicenter study.2025Journal of inherited metabolic disease
中文论文(未计入)1
  1. [Advances in the specific treatments of Pompe disease].2023Zhonghua nei ke za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)即将招募NCT06178432牵头方早期I期2023-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

上海有 12 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文1
  1. Pseudoexon activating by a deep intronic variant and phenotype variation in a Chinese family with dystrophinopathy.2025Journal of human genetics
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy已完成NCT03760029研究中心不分期2019-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

上海有 15 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
牵头的论文1
  1. Successful treatment of Behçet's disease ulcers and skin lesions with hydrogen water.2024International journal of dermatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.8%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 3320242025: 002025

上海有 26 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文6
  1. Renal outcomes in IgA nephropathy following inactivated SARS-CoV-2 vaccination.2024Clinical and experimental nephrology
  2. Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Self-Controlled Study.2024Kidney & blood pressure research
  3. Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China.2024Renal failure
  4. Exploring genes for immunoglobulin A nephropathy: a summary data-based mendelian randomization and FUMA analysis.2023BMC medical genomics
  5. Mesangial cell-derived tenascin-C contributes to mesangial cell proliferation and matrix protein production in IgA nephropathy.2022Nephrology (Carlton, Vic.)
  6. KM55 Monoclonal Antibody Staining in IgA-Dominant Infection-Related Glomerulonephritis.2021Nephron
早期论文(2016–2020 年)2
  1. Renal Outcomes of Pregnant Patients with Immunoglobulin A Nephropathy: A Systematic Review and Meta-Analysis.2019American journal of nephrology
  2. Abnormal glucose metabolism and galactose-deficient immunoglobulin A1 (IgA1) synthesis: a possible mechanism of IgA nephropathy.2019Discovery medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases进行中,不再招募NCT06786338研究中心II期2025-06 启动
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  3. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 17 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Primary biliary cirrhosis degree assessment by acoustic radiation force impulse imaging and hepatic fibrosis indicators.2016World journal of gastroenterology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 13 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

上海有 7 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年中国大陆作者发表的 32 篇遗传性血管性水肿 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

上海有 2 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

复旦大学附属华山医院

Huashan Hospital

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Huashan Hospital Fudan University; Huashan Hospital & Cancer Metastasis Institute; Huashan Hospital North; Huashan Hospital of Fudan University; Huashan Hospital Affiliated to Fudan University; Fudan University Huashan Hospital; Huashan Hospital Shanghai Medical College; Huashan Hospital and Cancer Metastasis Institute

提出更正下载数据